newsfilter
← Latest News
GlobeNewswire·

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

KA

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors